These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 20206400)

  • 1. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.
    Nguyen T; Thompson AJ; Bowden S; Croagh C; Bell S; Desmond PV; Levy M; Locarnini SA
    J Hepatol; 2010 Apr; 52(4):508-13. PubMed ID: 20206400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.
    Zeng LY; Lian JS; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD
    World J Gastroenterol; 2014 Jul; 20(27):9178-84. PubMed ID: 25083092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection.
    Wang L; Zou ZQ; Wang K; Yu JG; Liu XZ
    Hepatol Int; 2016 Jan; 10(1):133-8. PubMed ID: 26427997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.
    Chung KH; Kim W; Kim BG; Lee HY; Jin E; Cho Y; Seo JY; Kim HY; Jung YJ; Kim JW; Jeong JB; Lee KL
    Gut Liver; 2015 Sep; 9(5):657-64. PubMed ID: 25717049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study.
    Jia W; Song LW; Fang YQ; Wu XF; Liu DY; Xu C; Wang XM; Wang W; Lv DX; Li J; Deng YQ; Wang Y; Huo N; Yu M; Xi HL; Liu D; Zhou YX; Wang GQ; Xia NS; Zhang MX
    Medicine (Baltimore); 2014 Dec; 93(29):e322. PubMed ID: 25546679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The change of the quantitative HBsAg level during the natural course of chronic hepatitis B.
    Kim YJ; Cho HC; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    Liver Int; 2011 Jul; 31(6):817-23. PubMed ID: 21645212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.
    Jaroszewicz J; Calle Serrano B; Wursthorn K; Deterding K; Schlue J; Raupach R; Flisiak R; Bock CT; Manns MP; Wedemeyer H; Cornberg M
    J Hepatol; 2010 Apr; 52(4):514-22. PubMed ID: 20207438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg titers in the different phases of hepatitis B infection in Syrian patients.
    Antaki N; Zeidane N; Alhaj N; Hadad M; Baroudi O; Antaki F; Abouharb R; Haffar S; Abdelwahab J; Alideeb S; Asaad F; Aljesri A; Doghman D; Aaraj R; Ibrahim N; Ali A; Assil M; Sabah H; Katranji N; Kebbewar K
    J Clin Virol; 2012 Jan; 53(1):60-4. PubMed ID: 22079974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
    Tseng TC; Kao JH
    J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection.
    Li W; Zhao J; Zou Z; Liu Y; Li B; Sun Y; Li X; Liu S; Cai S; Yao W; Xin S; Lu F; Xu D
    PLoS One; 2014; 9(2):e89046. PubMed ID: 24551214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
    Liu C; Wu W; Shang S; Huang E; Xun Z; Lin J; Chen T; Yang B; Chen J; Ou Q
    J Med Virol; 2019 Feb; 91(2):249-257. PubMed ID: 30011350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HBsAg quantification in treatment-naïve Indian patients with chronic hepatitis B.
    Ramachandran J; Ismail AM; Chawla G; Fletcher GJ; Goel A; Eapen CE; Abraham P
    Indian J Gastroenterol; 2014 Mar; 33(2):131-5. PubMed ID: 24052375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.